☆ 4.7 Meeting Abstract

Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET

ANNALS OF ONCOLOGY (2020)

Journal

ANNALS OF ONCOLOGY

Volume 31, Issue -, Pages S1166-S1166

Publisher

ELSEVIER

DOI: 10.1016/j.annonc.2020.08.2266

Keywords

-

Categories

Oncology

Funding

GlaxoSmithKline, Waltham, MA, USA

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Multidisciplinary Sciences

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C. Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie Lheureux

Summary: This phase II trial evaluated the efficacy of niraparib monotherapy or in combination with dostarlimab in patients with recurrent serous or endometrioid endometrial carcinoma. The results showed that niraparib monotherapy did not meet the efficacy threshold, but the combination with dostarlimab showed modest activity. Limited treatment options and poor response rates to chemotherapy are challenges in recurrent endometrial carcinoma.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M. O'Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath, Wei Guo, Ellie Im, Sybil Zildjian, Xinwei Han, Tao Duan, Jennifer Veneris, Bhavana Pothuri

Summary: Dostarlimab demonstrated durable antitumor activity in patients with endometrial cancer, with a manageable safety profile.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

Ana Oaknin, Anna Tinker, Lucy Gilbert, Vanessa Samouelian, Cara Mathews, Jubilee Brown, Maria-Pilar Barretina-Ginesta, Victor Moreno, Adriano Gravina, Cyril Abdeddaim, Susana Banerjee, Wei Guo, Hadi Danaee, Ellie Im, Renaud Sabatier

Summary: This document summarizes the GARNET trial, which focused on treating patients with dMMR endometrial cancer with dostarlimab and showed efficacy in shrinking tumors in some patients. The percentage of participants experiencing side effects was low and within expectations for this type of treatment.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

M. R. Mirza, D. M. Chase, B. M. Slomovitz, R. dePont Christensen, Z. Novak, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L. M. Landrum, L. C. Hanker, A. Stuckey, I. Boere, M. A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. S. Shahin, S. E. Gill, B. J. Monk, J. Buscema, T. J. Herzog, L. J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R. L. Coleman, M. A. Powell

Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma

Camilla Di Dio, Giorgio Bogani, Violante Di Donato, Ilaria Cuccu, Ludovico Muzii, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso

Summary: Endometrial cancer is a heterogeneous disease with specific genomic, molecular, and biological features. Immune checkpoint inhibitors and tyrosine kinase inhibitors have shown promising results in the treatment of advanced or recurrent endometrial cancer. The combination of pembrolizumab and lenvatinib has become the new standard second-line treatment, regardless of the MMR status. Further studies are exploring the use of immune checkpoint inhibitors and PARP inhibitors in combination therapy.

GYNECOLOGIC ONCOLOGY (2023)

Add to Collection

Article Oncology

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer

Cara Mathews, Domenica Lorusso, Robert L. Coleman, Susan Boklage, Jamie Garside

Summary: This study found that dostarlimab has favorable efficacy and safety profiles for patients with dMMR/MSI-H advanced/recurrent endometrial cancer through an indirect treatment comparison.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

Valentina Tuninetti, Luca Pace, Eleonora Ghisoni, Virginia Quara, Francesca Arezzo, Andrea Palicelli, Vincenzo Dario Mandato, Elena Geuna, Gennaro Cormio, Nicoletta Biglia, Lucia Borsotti, Silvia Gallo, Annamaria Ferrero, Elena Jacomuzzi, Luca Fuso, Jeremy Oscar Smith Pezua Sanjinez, Andrea Puppo, Andrea Caglio, Chiara Rognone, Margherita Turinetto, Giulia Scotto, Massimo Di Maio, Giorgio Valabrega

Summary: Endometrial cancer (EC) is the most common gynecological malignancy, and there has been an increase in incidence and disease-related mortality in recent years. Limited data is available on the response to first-line carboplatin plus paclitaxel in EC. The retrospective RAME study aimed to assess chemotherapy response in MSI-h/dMMR and MSI-l/pMMR EC patients, and found that patients with MSI-l/pMMR had numerically longer PFS and OS compared to MSI-h/dMMR patients in the first-line setting.

CANCERS (2023)

Add to Collection

Article Oncology

Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis

Kun Liu, Youwen Zhu, Yangying Zhou, Yu Zhang, Hong Zhu

Summary: This study compared the cost-effectiveness of pembrolizumab plus lenvatinib (PL) with chemotherapy for the treatment of mismatch repair-proficient (pMMR) advanced endometrial cancer. The results showed that, at a willingness-to-pay threshold of $150,000 per QALY, PL was the most cost-effective treatment strategy.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Review Oncology

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?

Laura Matteucci, Alessandro Bittoni, Graziana Gallo, Laura Ridolfi, Alessandro Passardi

Summary: The majority of metastatic colorectal cancer cases are resistant to Immune Checkpoint Inhibitors, but there are strategies to overcome this resistance and expand the use of immunotherapy, including combination with chemotherapy and targeted drugs, sequential treatment with specific drugs, and validation of immunohistochemical biomarkers.

CANCERS (2023)

Add to Collection

Article Oncology

The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis

P. -S. Kok, Y. C. Antill, C. L. Scott, C. K. Lee

Summary: This meta-analysis showed that single-agent ICI had significantly higher objective response rate and longer progression-free survival in patients with dMMR compared to those with pMMR in advanced endometrial cancer.

ESMO OPEN (2022)

Add to Collection

Article Medicine, General & Internal

Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/miscrosatellite-stable type endometrial cancer: A case report

Chong-Ya Zhai, Lu-Xi Yin, Wei-Dong Han

Summary: Endometrial cancer (EC) is a common cancer of the female reproductive tract, and immunotherapy with PD-1 inhibitors shows promise for refractory cases. Molecular testing is crucial for clinical classifications of EC, and combination PD-1 inhibitor treatment has shown positive outcomes in cases with proficient mismatch repair (pMMR)/microsatellite-stable (MSS) EC. Further clinical exploration is warranted based on these results.

WORLD JOURNAL OF CLINICAL CASES (2022)

Add to Collection

Article Multidisciplinary Sciences

A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer

Cheng Wang, Wei Kuang, Jing Zeng, Yang Ren, Qianqi Liu, Huanxin Sun, Min Feng, Dongni Liang

Summary: This study evaluates the utility of immunohistochemistry (IHC) staining and PCR-based microsatellite instability (MSI) analysis in endometrial cancer. The results show that the combined use of MMR-IHC and PCR-CE MSI analysis can effectively prevent misdiagnosis in patients with mismatch repair deficiency or high microsatellite instability, particularly in patients with MSH6 deficiency and microsatellite stable tumors.

PEERJ (2023)

Add to Collection

Article Oncology

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes

Jin K. Kim, Chin-Tung Chen, Ajaratu Keshinro, Asama Khan, Canan Firat, Chad Vanderbilt, Neil Segal, Zsofia Stadler, Jinru Shia, Vinod P. Balachandran, Martin R. Weiser

Summary: T cells in colon tumors with deficient DNA mismatch repair (dMMR) are more clonal and have a less diverse repertoire compared to tumors with proficient mismatch repair (pMMR). This suggests that T cells clonally expand in response to MMR deficiency-induced tumor neoantigens in dMMR tumors.

ONCOIMMUNOLOGY (2022)

Add to Collection

Article Oncology

Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States

Sneha S. Kelkar, Vimalanand S. Prabhu, Shelby Corman, Shardul Odak, Nifasha Rusibamayila, Cynthia Macahilig, Robert Orlowski, Linda Duska

Summary: The objective of this study was to assess clinical outcomes and treatment patterns among MSI-H/dMMR aEC patients who had disease progression following prior systemic therapy (FPST) in the US. The study found that pembrolizumab monotherapy provides considerable clinical benefits and has become the standard of care for MSI-H/dMMR aEC patients FPST who are not candidates for curative surgery in real-world settings.

GYNECOLOGIC ONCOLOGY (2023)

Add to Collection

Article Economics

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

Raquel Aguiar-Ibanez, Chloe Hardern, Frank van Hees, Dawn Lee, Anubhav Patel, Nitika Chhabra, Gargi Baluni, Mayur Amonkar, Yizhen Lai, Ruifeng Xu, Rachid Massaad, David Fogelman

Summary: This study evaluated the cost-effectiveness of Pembrolizumab as a first-line treatment for MSI-H/dMMR CRC patients and concluded that Pembrolizumab is highly cost-effective.

JOURNAL OF MEDICAL ECONOMICS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of patient engagement in a French telemonitoring programme for heart failure on hospitalization and mortality

Remi Sabatier, Damien Legallois, Mouna Jodar, Laurene Courouve, Valerie Donio, Florence Boudevin, Thibault De Chalus, Karine Hauchard, Annette Belin, Paul Milliez

Summary: This study evaluated the impact of patient engagement in home-based telemonitoring for heart failure on rehospitalization and mortality rates. It found significant associations between the level of patient engagement and rehospitalization and mortality rates.

ESC HEART FAILURE (2022)

Add to Collection

Meeting Abstract Oncology

Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study

T. Andre, D. Berton-Rigaud, G. Curigliano, R. Sabatier, A. V. Tinker, A. Oaknin, F. G. M. De Braud, S. Ellard, H-T. Arkenau, J. M. Trigo Perez, J. Brown, A. Jewell, J. Pikiel, M. R. Mirza, T. Duan, G. Antony, S. Zildjian, E. Zografos, J. Veneris, S. Banerjee

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) a randomised, open-label, multicentre, phase 3 trial

Francois-Clement Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Thibault de la Motte Rouge, Renaud Sabatier, Coraline Dubot, Jean-Sebastien Frenel, Jean Marc Ferrero, Sylvain Ladoire, Christelle Levy, Marie-Ange Mouret-Reynier, Alain Lortholary, Julien Grenier, Camille Chakiba, Laetitia Stefani, Jerome Edouard Plaza, Florian Clatot, Luis Teixeira, Veronique D'Hondt, Helene Vegas, Olfa Derbel, Claire Garnier-Tixidre, Jean-Luc Canon, Barbara Pistilli, Fabrice Andre, Laurent Arnould, Anne Pradines, Ivan Bieche, Celine Callens, Jerome Lemonnier, Frederique Berger, Suzette Delaloge

Summary: The PADA-1 trial aimed to show the efficacy of early therapeutic targeting of rising ESR₁ mutation in blood (bESR₁(mut)), while assessing the safety of combination fulvestrant and palbociclib. Results demonstrated that early therapeutic targeting of bESR₁(mut) resulted in significant clinical benefit.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

A 2022 inventory in oncology news

Jacques-Olivier Bay, Carole Bouleuc, Christophe Caux, Frederic Delom, Nelly Firmin, Virginie Gandemer, Gilles L'Allemain, Nicolas Magne, Daniel Orbach, Jacques Robert, Manuel Rodrigues, Renaud Sabatier, Antoine Thiery-Vuillemin, Marie Wislez

Summary: This article presents the analysis of highlights from 2022 by the editorial committee members of The Cancer Bulletin. Their objective is to provide readers with a thoughtful, educational, and practical reading by analyzing published data and placing it in the context of cancer management. The goal is to offer rational bases for different treatment approaches in 2023.

BULLETIN DU CANCER (2023)

Add to Collection

Article Oncology

Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, Laurence Gladieff, Christophe Pomel, Pierre-Emmanuel Colombo, Jean-Marc Classe, Marion Chevrier, Florence Joly, Thibault De la Motte Rouge, Anne Floquet, Renaud Sabatier, Emmanuel Barranger, Helene Costaz, Eric Leblanc, Frederic Marchal, Patricia Pautier, Lise Bosquet, Manuel Rodrigues

Summary: Chemotherapy options for platinum-sensitive relapse of high-grade serous ovarian cancers include carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. BRCA mutated patients are sensitive to replicative stress agents, but BRCA status is not currently used for chemotherapy selection. This study aimed to assess the effectiveness of these doublets according to BRCA status in first platinum-sensitive relapse.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

Add to Collection

Article Oncology

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Gwenaelle Gravis, Patricia Marino, Daniel Olive, Frederique Penault-LLorca, Jean-Pierre Delord, Clotilde Simon, Assia Lamrani-Ghaouti, Renaud Sabatier, Joseph Ciccolini, Jean-Marie Boher

Summary: The study aims to investigate whether reducing the dose and frequency of immunotherapy after 6 months of standard treatment can maintain the efficacy for metastatic cancer. A total of 646 patients will be recruited and randomly assigned into two groups, standard immunotherapy group and reduced intensity group, to compare their efficacy, survival rate, and toxicity. This study could provide insights into a more cost-effective, less toxic, and improved quality of life treatment approach.

BMC CANCER (2023)

Add to Collection

Article Oncology

Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged & GE;65 years from the PAOLA-1/ENGOT-ov25 trial

Renaud Sabatier, Frederique Rousseau, Florence Joly, Claire Cropet, Coline Montegut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alia, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Remi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marme, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard

Summary: In the PAOLA-1 study, maintenance olaparib plus bevacizumab was found to improve progression-free survival in older patients with advanced ovarian cancer, with similar efficacy and safety to younger patients.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Medicine, Research & Experimental

Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network

Elsa Nigon, Claudia Lefeuvre-Plesse, Alejandra Martinez, Celine Chauleur, Alain Lortholary, Laure Favier, Anne-Sophie Bats, Arnaud Guille, Jose Adelaide, Pascal Finetti, Victoire de Casteljac, Magali Provansal, Emilie Mamessier, Francois Bertucci, Isabelle Ray-Coquard, Renaud Sabatier

Summary: This multicenter retrospective study aimed to explore the clinical and molecular features of uterine clear cell carcinomas. The study found that most patients with uterine CCC were diagnosed at an early stage and received surgery, radiation, and chemotherapy as treatments. Some patients showed immune response-associated features and had a better prognosis.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Oncology

Real-world dostarlimab use in advanced/ recurrent endometrial cancer in France

Manuel Rodrigues, Lauriane Eberst, Philippe Follana, Ludiane Gauthier, Virginie Jacquemin, Christophe Tessier, Nadia El Mouaddin, Philippe Boudier, Frederic Fiteni, Eurydice Angeli, Sophie Roche, Nicolas Delanoy, Renaud Sabatier, Ronan Flippot, Thibault de la Motte Rouge

Summary: This study conducted a descriptive analysis of patients granted temporary authorization to use dostarlimab, finding that the treatment response rate and disease control rate were consistent with clinical trial results. The study highlights the need for novel treatment options for patients in France who have undergone platinum-based therapy.

BULLETIN DU CANCER (2023)

Add to Collection

Article Medicine, General & Internal

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors A Nonrandomized Controlled Trial

Thierry Andre, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V. Tinker, Ana Oaknin, Susan Ellard, Filippo de Braud, Hendrik-Tobias Arkenau, Jose Trigo, Adriano Gravina, Rebecca Kristeleit, Victor Moreno, Cyril Abdeddaim, Yann-Alexandre Vano, Vanessa Samouelian, Rowan Miller, Valentina Boni, Antonio Anton Torres, Lucy Gilbert, Jubilee Brown, Ninad Dewal, Christine Dabrowski, Grace Antony, Eleftherios Zografos, Jennifer Veneris, Susana Banerjee

Summary: In this trial, dostarlimab showed well-tolerated treatment option with rapid, robust, and durable antitumor activity in patients with diverse dMMR solid tumors. These findings suggest that dostarlimab provides meaningful long-term benefit in a population with high unmet need.

JAMA NETWORK OPEN (2023)

Add to Collection

Meeting Abstract Oncology

Antitumor activity of dostarlimab in patients with advanced or recurrent mismatch repair-deficient or -proficient cancer by prior therapy: Results from the GARNET study

Lars Hanker, Ana Oaknin, Lucy Gilbert, Anna Tinker, Jubilee Brown, Cara Matthews, Joshua Press, Renaud Sabatier, David O'malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath, Jennifer Veneris, Tao Duan, Ellie Im, Bhavana Pothuri

ONCOLOGY RESEARCH AND TREATMENT (2022)

Add to Collection

Meeting Abstract Oncology

Antitumor activity and safety of dostarlimab therapy in patients (pts) with endometrial cancer (EC) by age subgroups: a post-hoc analysis from the GARNET trial

Lars Hanker, Ana Oaknin, Lucy Gilbert, Anna Tinker, Renaud Sabatier, Jubilee Brown, Cara Matthews, Valentina Boni, Vanessa Samouelian, David O'malley, Andrea Jewell, Susana Banerjee, Grace Antony, Jennifer Veneris, Bhavana Pothuri

ONCOLOGY RESEARCH AND TREATMENT (2022)

Add to Collection

Meeting Abstract Oncology

Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Sharad Ghamande, Adriano Gravina, Emiliano Calvo, Susana Banerjee, Niamh Mangan, Rowan E. Miller, Joanna Pikiel, Mansoor R. Mirza, Tao Duan, Sybil Zildjian, Eleftherios Zografos, Jennifer Veneris, Anna V. Tinker

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Sharad A. Ghamande, Adriano Gravina, Emiliano Calvo, Susana N. Banerjee, Rowan Miller, Joanna Pikiel, Mansoor Raza Mirza, Tao Duan, Sybil Zildjian, Eleftherios Zografos, Jennifer Taylor Veneris, Anna Tinker, Matthew A. Powell

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

A non-inferiority randomized phase III trial of standard immunotherapy versus reduced dose intensity in responding patients with metastatic cancer: MOIO study

Gwenaelle Gravis, Daniel Olive, Patricia Marino, Frederique Madeleine Penault-Llorca, Jean-Pierre Delord, Assia Lamrani-Ghaouti, Clotilde Simon, Renaud Sabatier, Joseph Ciccolini, Jean-Marie Boher

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.